ATE429645T1 - Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten - Google Patents

Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten

Info

Publication number
ATE429645T1
ATE429645T1 AT05811604T AT05811604T ATE429645T1 AT E429645 T1 ATE429645 T1 AT E429645T1 AT 05811604 T AT05811604 T AT 05811604T AT 05811604 T AT05811604 T AT 05811604T AT E429645 T1 ATE429645 T1 AT E429645T1
Authority
AT
Austria
Prior art keywords
neurodegenerative diseases
eph receptor
receptor inhibitors
treat neurodegenerative
inhibitors
Prior art date
Application number
AT05811604T
Other languages
English (en)
Inventor
Carsten Hopf
Gerard Drewes
Original Assignee
Cellzome Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ag filed Critical Cellzome Ag
Application granted granted Critical
Publication of ATE429645T1 publication Critical patent/ATE429645T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT05811604T 2004-11-25 2005-11-25 Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten ATE429645T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04028046A EP1662259A1 (de) 2004-11-25 2004-11-25 Verwendung von Eph Rezeptor-Inhibitoren zur Behandlung von neurodegenerativen Erkrankungen
US63059204P 2004-11-26 2004-11-26
PCT/EP2005/012649 WO2006056467A1 (en) 2004-11-25 2005-11-25 Use of eph receptor inhibitors for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ATE429645T1 true ATE429645T1 (de) 2009-05-15

Family

ID=34927535

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05811604T ATE429645T1 (de) 2004-11-25 2005-11-25 Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten

Country Status (6)

Country Link
US (1) US20080213250A1 (de)
EP (2) EP1662259A1 (de)
AT (1) ATE429645T1 (de)
CA (1) CA2589173A1 (de)
DE (1) DE602005014134D1 (de)
WO (1) WO2006056467A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006255536A1 (en) * 2005-06-03 2006-12-14 Novartis Vaccines And Diagnostics Inc. Methods of treating, diagnosing or detecting cancer using an EphB3 modulator
ES2508893T3 (es) 2006-01-05 2014-10-16 The Ohio State University Research Foundation Métodos basados en microARN para el diagnóstico de cánceres de estómago
EP2371971B1 (de) 2006-03-20 2013-11-27 The Ohio State University Research Foundation Mikro-RNA-Fingerabdrücke während humaner Megakaryozytopoiese
DE602006004196D1 (de) * 2006-06-01 2009-01-22 Cellzome Ag Verfahren zur Identifizierung von mit ZAP-70 wechselwirkenden Molekülen und zur ZAP-70-Reinigung
GB0624689D0 (en) * 2006-12-11 2007-01-17 Glaxo Group Ltd Novel fluorescent kinase ligands and methods employing the same
CA2680589A1 (en) * 2007-03-14 2008-09-18 Universita' Degli Studi Di Milano - Bicocca Modulator compounds of the drug resistance in epithelial tumour cells
JP5511377B2 (ja) * 2007-06-08 2014-06-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 γ−セクレターゼの新規基質EphA4を利用したスクリーニング方法
US20090191580A1 (en) * 2007-07-19 2009-07-30 Eisai R & D Management Co., Ltd. METHOD OF SCREENING USING c-MET, A NOVEL SUBSTRATE FOR GAMMA-SECRETASE
US20100190184A1 (en) * 2007-08-01 2010-07-29 Eisai R & D Management Co., Ltd. Screening method utilizing novel substrate c-ret for gamma-secretase
EP2173908B1 (de) 2007-08-03 2016-01-06 The Ohio State University Research Foundation Ultrakonservierte bereiche zur kodierung von ncrnas
WO2009026487A1 (en) * 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
EP2219028B1 (de) * 2007-11-15 2012-09-12 Eisai R&D Management Co., Ltd. Screening-verfahren mit nutzung des neuen substrats epha7 für gamma-sekretase
JP5508857B2 (ja) * 2007-11-30 2014-06-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規活性を有するEphA4ポリペプチドおよびその用途
US20100197688A1 (en) * 2008-05-29 2010-08-05 Nantermet Philippe G Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US20100113415A1 (en) * 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US8652478B2 (en) 2008-06-09 2014-02-18 Oxford Biotherapeutics Ltd. Method for treating cancer by administering antibody to ephrin type-A receptor 7
WO2010114921A1 (en) * 2009-04-02 2010-10-07 Burnham Institute For Medical Research Eph receptor ligands and methods of use
WO2010141974A1 (en) * 2009-06-10 2010-12-16 The University Of Melbourne Therapeutic applications
US8159780B2 (en) 2009-07-15 2012-04-17 Seagate Technology Llc Recording head heater systems with two electrical connections
EP2483406A2 (de) 2009-09-30 2012-08-08 President and Fellows of Harvard College Verfahren zur autophagie-modulation durch modulation autophagie-hemmender genprodukte
CN103648505B (zh) 2010-11-12 2016-09-28 俄亥俄州立大学研究基金会 与微rna-21、错配修复和结肠直肠癌相关的材料和方法
AU2011329066B2 (en) 2010-11-15 2017-03-09 The Ohio State University Research Foundation Controlled release mucoadhesive systems
US9101644B2 (en) 2010-11-15 2015-08-11 The J. David Gladstone Institutes Methods of treating neurodegenerative disease
JP6059017B2 (ja) 2010-12-17 2017-01-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法
WO2012147798A1 (ja) 2011-04-25 2012-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 EphA4細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
WO2013056217A1 (en) 2011-10-14 2013-04-18 The Ohio State University Methods and materials related to ovarian cancer
CN104619353A (zh) 2011-12-13 2015-05-13 俄亥俄州国家创新基金会 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
WO2013110053A1 (en) 2012-01-20 2013-07-25 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
CN111320693B (zh) * 2015-09-08 2023-04-07 卫材R&D管理有限公司 抗EphA4抗体
NZ783106A (en) 2019-07-01 2025-08-29 Eisai R&D Man Co Ltd Anti-epha4 antibody
JP2024540616A (ja) * 2021-11-22 2024-10-31 チャイナ メディカル ユニバーシティ エフリンa型受容体10に特異的な抗体、それを含有する融合タンパク質、それを発現するキメラ抗原受容体t細胞及びその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2548699A (en) * 1998-02-23 1999-09-06 Rei Asakai Cell death inhibitors
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
IL162838A0 (en) * 2002-01-04 2005-11-20 Univ Rockefeller Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
KR20050008787A (ko) * 2002-06-05 2005-01-21 얀센 파마슈티카 엔.브이. 키나제 저해제로서의 비스인돌릴-말레이미드 유도체
AU2003268345A1 (en) * 2002-09-24 2004-04-19 The Burnham Institute Novel agents that modulate eph receptor activity

Also Published As

Publication number Publication date
DE602005014134D1 (de) 2009-06-04
CA2589173A1 (en) 2006-06-01
US20080213250A1 (en) 2008-09-04
EP1815255B1 (de) 2009-04-22
WO2006056467A1 (en) 2006-06-01
EP1662259A1 (de) 2006-05-31
EP1815255A1 (de) 2007-08-08

Similar Documents

Publication Publication Date Title
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
MX2010002674A (es) Moduladores de gamma secretasa.
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
MX2010006379A (es) Moduladores de la secretasa gamma.
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
MX2010005028A (es) Moduladores de gamma secretasa.
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
EP1881823A4 (de) Zusammensetzungen und verfahren zur behandlung von augenleiden
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
TNSN07027A1 (en) Pyrrolo-pyridine kinase modulators
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DE602006018354D1 (de) Verfahren zur behandlung von abnormalem zellwachstum
EP1732484A4 (de) Ophthalmisches implantat zur behandlung von glaukom
EA202091559A1 (ru) Способ получения модуляторов соматостатина
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
ATE421501T1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
NO20073369L (no) Modulatorer av muskarinreseptorer
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
WO2010147969A3 (en) Gamma secretase modulators
MX2010001501A (es) Moduladores de gamma secretasa.
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties